Abstracts Archive - Page 2334 of 2607 - ACR Meeting Abstracts

Abstract Number: 1458 • 2013 ACR/ARHP Annual Meeting
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
A Nadkarni, F Lobo and T Juday, Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Several biologic disease-modifying antirheumatic drugs (bDMARDs) are approved for the treatment of moderate-to-severe RA. Switching between bDMARD therapies is common in real-world settings, and…
Abstract Number: 1472 • 2013 ACR/ARHP Annual Meeting
Discontinuation Rates Of Tocilizumab Therapy In Rheumatoid Arthritis Patients In a Nonacademic Clinical Setting
Jaishree Manohar¹ and Charles H. Pritchard², ¹Rheumatology, Drexel University College of Medicine, Sarasota, FL, ²Rheumatology, Drexel University College of Medicine, Willow Grove, PA
Background/Purpose: Tocilizumab(TCZ) and other biologics are expensive and switching between them is difficult. The goal of this retrospective chart analysis is to identify the discontinuation…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 1459 • 2013 ACR/ARHP Annual Meeting
Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Kensuke Koyama¹, Katsunori Ikari¹, Atsuo Taniguchi², Shigeki Momohara² and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid…
Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
I.M. Markusse¹, G. Akdemir¹, M. van den Broek¹, L. Dirven¹, R.J. Goekoop², K.H. Han³, M. van Oosterhout⁴, P.J.S.M. Kerstens⁵, W.F. Lems⁶, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…
Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Boulos Haraoui¹, Algis V Jovaisas², William G. Bensen³, Rafat Y. Faraawi⁴, John T. Kelsall⁵, Sanjay Dixit⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, Francois Nantel⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 1463 • 2013 ACR/ARHP Annual Meeting
Dietary Impact On Treatment Results Of Methotrexate In Patients With Rheumatoid Arthritis
Cecilia Lourdudoss¹, Alicja Wolk², Camilla Bengtsson³, Lena Nise⁴, Lars Alfredsson³ and Ronald van Vollenhoven⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska institutet, Stockholm, Sweden, ²Institute of Environmental Medicine (IMM), Karolinska institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose: Some specific diets have been shown to ameliorate rheumatoid arthritis (RA). However, there is generally a lack of studies on any possible dietary impact…
Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 1465 • 2013 ACR/ARHP Annual Meeting
Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
H Nüßlein¹, R Alten², M Galeazzi³, H M Lorenz⁴, D Boumpas⁵, M T Nurmohamed⁶, W G Bensen⁷, Gerd Burmester⁸, H-H Peter⁹, F Rainer¹⁰, K Pavelka¹¹, M Chartier¹², C Poncet¹³, C Rauch¹⁴ and M Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital/McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Nanterre, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Reduced efficacy for achieving DAS28 30 kg/m2,1 which in theory could induce dose increases to maintain efficacy. Here we explore adherence to abatacept over…
Abstract Number: 1466 • 2013 ACR/ARHP Annual Meeting
Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy?
Ennio G. Favalli¹, Martina Biggioggero², Antonio Marchesoni³ and Pier Luigi Meroni², ¹Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, Milan, Italy, ²Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ³UOC Day Hospital Rheumatology, Gaetano Pini Institute, Milan, Italy, Milano, Italy
Background/Purpose: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor is still an unclear aspect in…
Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting
Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Ghada Ahmed¹, Sandra L Goss¹, Cheri E Klein¹, Neelufar Mozaffarian², Gurjit S. Kaeley³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²Eli Lilly, San Diego, CA, ³College of Medicine, University of Florida, Jacksonville, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
Abstract Number: 1468 • 2013 ACR/ARHP Annual Meeting
Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Martin J. Bergman², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Kristin King⁴, Jae Oh⁴, Monarch Shah¹ and Max I. Hamburger⁵, ¹ICON Clinical Research, San Francisco, CA, ²Taylor Hospital, Ridley Park, PA, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Rheumatology Associates, Melville, NY
Background/Purpose: Results from randomized controlled trials indicate that about one-third of rheumatoid arthritis (RA) patients initially treated with anti-TNF agents do not respond, show a…
Abstract Number: 1469 • 2013 ACR/ARHP Annual Meeting
Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1^st Anti-TNF: Results of the Multicenter Randomized Controlled “ROC” Trial
Jacques-Eric Gottenberg¹, Olivier Brocq², Aleth Perdriger³, Slim Lassoued⁴, Jean-Marie Berthelot⁵, Daniel Wendling⁶, Liana E. euller-Ziegler⁷, Martin Soubrier⁸, Christophe Richez⁹, Bruno Fautrel¹⁰, Arnaud L. Constantin¹¹, Xavier Mariette¹², Jacques Morel¹³, Melanie Gilson¹⁴, Grégoire Cormier¹⁵, Jean Hugues Salmon¹⁶, Stephanie Rist¹⁷, Frédéric Liote¹⁸, Hubert Marotte¹⁹, Christine Bonnet²⁰, Christian Marcelli²¹, Jeremie Sellam²², Olivier Meyer²³, Elisabeth Solau-Gervais²⁴, Sandrine Guis²⁵, Jean-Marc Ziza²⁶, Charles Zarnitsky²⁷, Isabelle Valckenaere²⁸, Olivier Vittecoq²⁹, Alain Saraux³⁰, Yves-Marie Pers³¹, Martine Gayraud³², Gilles Bolla³³, Pascal Claudepierre³⁴, Marc Ardizzone³⁵, Emmanuelle Dernis³⁶, Maxime A. Breban³⁷, Olivier Fain³⁸, Jean-Charles Balblanc³⁹, Ouafaa Aberkane¹, Marion Vazel¹, Christelle Back¹, Elodie Perrodeau⁴⁰, Philippe Ravaud⁴¹ and Jean Sibilia⁴², ¹Strasbourg University Hospital, Strasbourg, France, ²Hospital of Princesse Grâce de Monaco, Monaco, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Cahors Hospital, Cahors, France, ⁵Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁶Rheumatology, University Hospital, Besancon, France, ⁷Service de Rhumatologie, L Archet Hospital (University), Nice CEDEX 3, France, ⁸Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ⁹Pellegrin Hospital, Bordeaux, France, ¹⁰Rheumatology, UPMC - Paris 6 University, Paris, France, ¹¹Rheumatology, Purpan University Hospital, Toulouse, France, ¹²Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹³Montpellier University Hospital, Montpellier, France, ¹⁴CH Grenoble Hopital Sud, Grenoble, France, ¹⁵CHD Les Oudairies, LA ROCHE SUR YON, France, ¹⁶Reims Hospital, Reims, France, ¹⁷Rheumatology, Orleans Hospital, Orleans, France, ¹⁸Hôpital Lariboisière, Paris, France, ¹⁹INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ²⁰department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ²¹Rheumatology Department, Caen University Hospital, CAEN, France, ²²Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, ²³Rheumatology, Hopital Bichat, Paris, France, ²⁴Poitiers University Hospital, Poitiers, France, ²⁵Rheumatology1, CRMBM UMR CNRS 7339, Aix Marseille Univ; AP-HM, Marseille, France, ²⁶Rheumatology, Croix Saint Simon Hospital, Paris, France, ²⁷Rheumatology, CH du Havre, Le Havre, France, ²⁸Nancy University Hospital, Nancy, France, ²⁹RouenUniversity Hospital, Rouen, France, ³⁰Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ³¹Department of Immuno-Rhumatology, CHU Lapeyronie, Montpellier, France, ³²Institut Montsouris, Paris, France, ³³Cannes Hospital, Cannes, France, ³⁴Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, ³⁵Mulhouse Hospital, Mulhouse, France, ³⁶Le Mans Hospital, Le Mans, France, ³⁷Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ³⁸Internal Medicine, Jean Verdier Hospital, Bondy, France, ³⁹Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ⁴⁰Epidemiology, Hotel Dieu, Paris, France, ⁴¹Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴²Rheumatology, CHU Hautepierre, Strasbourg, France
Background/Purpose: TNF inhibitors often represent the 1st biologic prescribed to patients with rheumatoid arthritis (RA). Approximately one third of patients fail to respond. However, therapeutic…
Abstract Number: 1470 • 2013 ACR/ARHP Annual Meeting
Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis
Paul A. MacMullan^1,2, Anne M. Madigan¹, Laura J. Durcan³, Karl Egan², Paola M. Bagaglia¹, Dermot Kenny⁴ and Geraldine M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Cardiovascular Biology Laboratory, RCSI, Dublin, Ireland, ³Rheumatology, Mater Misercordiae University Hospital, Dublin 7, Ireland, ⁴Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Patients with inflammatory arthritis (IA) die prematurely from cardiovascular disease (CVD). The increased CVD risk is not fully explained by traditional risk factors, but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].